Aktie A3E2FW TFF PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen TFF Pharmaceuticals, Inc.

Aktien

A3E2FW

US87241J2033

TFFP

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 25.06.2024 		% 5 Tage % 1. Jan.
1,97 USD +3,68 % Intraday Chart für TFF Pharmaceuticals, Inc. +1,03 % -71,94 %
24.06. Tff Pharmaceuticals, Inc. gibt ein regulatorisches Update zum klinischen Programm mit Tacrolimus-Inhalationspulver (Tff Tac) zur Prävention von Abstoßungsreaktionen bei Lungentransplantationen CI
23.05. TFF Pharmaceuticals und Leidos führen präklinische Tests an Gegenmitteln zur biologischen Verteidigung durch MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
TFF Pharmaceuticals, Inc. and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
TFF Pharmaceuticals Advances Influenza Vaccine Candidates Into Preclinical Testing
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
TFF Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals Files Equities Shelf
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3E2FW Aktie
  4. Nachrichten TFF Pharmaceuticals, Inc.
  5. Andere Sprachen